Sio Gene Therapies Inc. (SIOX)
(Delayed Data from OTC)
$0.48 USD
0.00 (0.00%)
Updated Feb 7, 2024 03:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Sio Gene Therapies Inc. [SIOX]
Reports for Purchase
Showing records 1 - 14 ( 14 total )
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage; Management Completely Unresponsive
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
Curtain Closes on AXO-AAV-GM1 and AXO-AAVGM2 Programs and Basically Sio; Downgrade to Sell
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
F3Q21 Results; Rare Disease Programs Continue to Mature; AXO-AAV-GM1 Data Update Expected Soon
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
Focus Is the Name of the Game for GMs; Price Target Adjusted to $7
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
F2Q21 Results; Momentum Builds Across Three Programs; Additional Pipeline Resolution in 1H22
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
Getting Ready to Welcome Back AXO-Lenti- PD Program; Most Focus on GM1/GM2 Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
AXO-AAV-GM1 Exhibits Durable Efficacy at 6 and 12 Months; Target Upped to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
Quickly Approaching Top-line Data Readout Brings AXO-AAV-GM1 Program Into Focus
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
AXO-AAV-GM1 Presses Play in Type I GM1 Gangliosidosis; Key Data Next Month
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
F1Q22 Results; AXO-AAV-GM1 Stays on Course to Provide Next Meaningful Update by Year''s End
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
F2021 Results; Active Pipeline Forecasts a Productive Year
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
ASGCT Presentation Underscores AXO-AAV-GM1''s Differentiated Efficacy and Durability
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
Outwitting Neurologic Disease With Transformative Gene Therapies; Initiating Coverage at Buy and $8 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Sio Gene Therapies Inc.
Industry: Medical - Biomedical and Genetics
|